{
  "company": {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000875320"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000875320-25-000232",
        "filingDate": "2025-11-04",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/vrtx-20250930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 3076.4,
        "netIncome": 1082.9,
        "operatingCashFlow": 3133.4,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 182,
        "marketShareMention": "Medicines being used to treat more than three quarters of approximately 94,000 people with CF in the U.S., Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 64.3,
          "Europe": 27.2,
          "Other": 8.5
        },
        "capexAmount": 288.2,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics gene-editing collaboration",
          "Zai Lab povetacicept licensing for China/Asia",
          "Ono Pharmaceuticals povetacicept licensing for Japan/South Korea"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong quarterly performance with $3.1B in revenue, driven by continued growth of cystic fibrosis portfolio and successful launches of ALYFTREK, CASGEVY, and JOURNAVX. The company maintains a robust pipeline across multiple therapeutic areas and continues to invest in R&D.",
        "keyQuotes": [
          "We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases",
          "Our five medicines, led by TRIKAFTA/KAFTRIO, are being used to treat more than three quarters of the approximately 94,000 people with CF"
        ],
        "marketData": {
          "priceOnEarningsDate": 391.6400146484375,
          "priceAfter7Days": 410.2799987792969,
          "priceChangePercent": 4.759468755405876,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 65,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000216",
        "filingDate": "2025-08-05",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/vrtx-20250630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 2944,
        "netIncome": 1032.9,
        "operatingCashFlow": 1892,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 146.9,
        "marketShareMention": "Our five medicines are treating more than three quarters of CF patients in the U.S., Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 62.1,
          "Europe": 30.9,
          "Other": 7
        },
        "capexAmount": 186.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics gene-editing collaboration",
          "Moderna CFTR mRNA therapy development",
          "Entrada Therapeutics myotonic dystrophy collaboration",
          "Zai Lab povetacicept out-licensing in China",
          "Ono Pharmaceuticals povetacicept out-licensing in Japan/Korea",
          "CRISPR Therapeutics",
          "Ono Pharmaceuticals",
          "Zai Lab",
          "Entrada Therapeutics",
          "Alphine Immune Sciences"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q2 2025 performance, with product revenues growing to $2.9 billion driven by continued TRIKAFTA/KAFTRIO demand and early contributions from new product launches in CF, sickle cell disease, and acute pain. The company maintains a robust pipeline across multiple therapeutic areas and continues to expand global market access.",
        "keyQuotes": [
          "We expect that the number of people with CF taking our medicines will continue to grow",
          "We have met our goal of activating more than 75 authorized treatment centers",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases"
        ],
        "marketData": {
          "priceOnEarningsDate": 445.20001220703125,
          "priceAfter7Days": 459.4100036621094,
          "priceChangePercent": 3.1918218925093056,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 70,
          "compositeSentimentScore": 64,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000192",
        "filingDate": "2025-05-06",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/vrtx-20250331.htm"
      },
      "insights": {
        "guidanceTone": "confident",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2770.2,
        "netIncome": 646.3,
        "operatingCashFlow": 818.9,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 228.4,
        "marketShareMention": "Nearly three quarters of ~94,000 people with CF in US, Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 59.9,
          "Europe": 29.9,
          "Other": 10.2
        },
        "capexAmount": 40.7,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene therapy)",
          "Moderna (CF mRNA therapy)",
          "Zai Lab (povetacicept licensing in Asia)",
          "CRISPR Therapeutics",
          "Entrada Therapeutics",
          "Zai Lab"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex continues to expand its market leadership in cystic fibrosis while diversifying into new therapeutic areas like sickle cell disease, pain management, and kidney diseases. Strong financial performance and multiple pipeline programs position the company for sustained growth.",
        "keyQuotes": [
          "We expect to grow our CF business by increasing the number of people with CF who are eligible and able to receive our medicines.",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities."
        ],
        "marketData": {
          "priceOnEarningsDate": 484.82000732421875,
          "priceAfter7Days": 474.55999755859375,
          "priceChangePercent": -2.1162513119562156,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 53,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000053",
        "filingDate": "2025-02-13",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": -8108.1,
        "netIncome": 1448.6,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR",
          "Moderna",
          "Entrada",
          "Zai"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Increasing drug pricing scrutiny",
          "Complex cell and gene therapy regulatory requirements",
          "Potential changes to healthcare laws and regulations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Vertex continues to focus on rare disease therapies, particularly in cystic fibrosis, sickle cell disease, and pain management. The company faces ongoing challenges with regulatory compliance, drug pricing pressures, and complex manufacturing requirements for cell and gene therapies.",
        "keyQuotes": [
          "Our success depends on our ability to successfully develop and commercialize additional products",
          "We continue to invest significant resources in the research and development of therapies for serious diseases and conditions"
        ],
        "marketData": {
          "priceOnEarningsDate": 402.70001220703125,
          "priceAfter7Days": 408.32000732421875,
          "priceChangePercent": 1.3955785812835326,
          "managementToneScore": 50,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000223",
        "filingDate": "2024-11-05",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/vrtx-20240930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2771.9,
        "netIncome": 1045.4,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 220,
        "marketShareMention": "nearly three quarters of approximately 92,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 61.8,
          "Europe": 30.6,
          "Other": 7.6
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for CASGEVY",
          "Moderna collaboration for VX-522 CF therapy"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q3 performance driven by TRIKAFTA/KAFTRIO global demand and pricing power. The company continues to expand its CF franchise, advance its gene therapy pipeline, and prepare for near-term product launches in CF and pain management.",
        "keyQuotes": [
          "We expect to grow our CF business with label expansions, continued uptake in younger patient groups, and growth in the number of people living with CF.",
          "We are preparing for near-term launches of potential new products in CF and acute pain."
        ],
        "marketData": {
          "priceOnEarningsDate": 465.0799865722656,
          "priceAfter7Days": 448.6000061035156,
          "priceChangePercent": -3.543472293918906,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 70,
          "compositeSentimentScore": 55,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000198",
        "filingDate": "2024-08-02",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/vrtx-20240630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2645.6,
        "netIncome": -3593.6,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 128.3,
        "marketShareMention": "CF medicines being used to treat nearly three quarters of ~92,000 CF patients in North America, Europe, Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 61,
          "Europe": 30.5,
          "Other": 8.5
        },
        "capexAmount": 137.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene-editing therapies)",
          "Moderna (CF mRNA therapy)",
          "Entrada Therapeutics (myotonic dystrophy)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Vertex delivered strong CF product revenues of $2.6B in Q2, driven by TRIKAFTA's performance. Acquired Alpine Immune Sciences for $5B to expand pipeline, with a strategic focus on rare diseases and specialty markets.",
        "keyQuotes": [
          "We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases",
          "We expect to grow our CF business with label expansions, continued uptake in younger patient groups, and growth in the number of people living with CF"
        ],
        "marketData": {
          "priceOnEarningsDate": 471.25,
          "priceAfter7Days": 481.8900146484375,
          "priceChangePercent": 2.2578280421087533,
          "managementToneScore": 70,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 54,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000139",
        "filingDate": "2024-05-07",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/vrtx-20240331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2690.6,
        "netIncome": 1099.6,
        "operatingCashFlow": 1306.6,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 275.8,
        "marketShareMention": "Continue to develop and expand CF treatment regimens",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 56.5,
          "Europe": 36,
          "Other": 7.5
        },
        "capexAmount": 68.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics for gene-editing therapies",
          "Moderna for CF mRNA therapy",
          "Entrada Therapeutics for myotonic dystrophy treatment",
          "Alpine Immune Sciences acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2024 performance, driven by continued robust growth in cystic fibrosis product sales and diversifying pipeline. The company is preparing for near-term launches in CF and acute pain while advancing multiple promising therapeutic programs.",
        "keyQuotes": [
          "Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines.",
          "We aim to rapidly follow our first-in-class therapies that achieve proof-of-concept with potential best-in-class candidates to provide durable clinical and commercial success."
        ],
        "marketData": {
          "priceOnEarningsDate": 420.4800109863281,
          "priceAfter7Days": 404.2200012207031,
          "priceChangePercent": -3.8670113538771034,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 90,
          "compositeSentimentScore": 59,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000062",
        "filingDate": "2024-02-15",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/vrtx-20231231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "expanding",
        "revenue": -7351.5,
        "netIncome": -2650.8,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Vertex is a leader in cystic fibrosis treatments",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Strategic agreement with Lonza for T1D cell therapy manufacturing",
          "Collaborations with CRISPR, Moderna, and Entrada"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Increasing drug pricing scrutiny",
          "Complex cell and genetic therapy regulatory requirements"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex continues to lead in cystic fibrosis treatments and is expanding into cell and genetic therapies like CASGEVY for sickle cell disease and thalassemia. The company is focused on developing therapies for rare diseases while navigating complex regulatory and pricing challenges.",
        "keyQuotes": [
          "We are focused on ensuring the stability of the supply chains for our current products",
          "We continue to invest significant resources in expanding and strengthening our manufacturing capabilities"
        ],
        "marketData": {
          "priceOnEarningsDate": 410.9100036621094,
          "priceAfter7Days": 419.1199951171875,
          "priceChangePercent": 1.9980023318753728,
          "managementToneScore": 85,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 55,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000031",
        "filingDate": "2023-11-07",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/vrtx-20230930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2483.5,
        "netIncome": 1035.3,
        "operatingCashFlow": 3302.7,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 157.1,
        "marketShareMention": "Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "UnitedStates": 62.6,
          "Europe": 30.9,
          "Other": 6.5
        },
        "capexAmount": 142.3,
        "capexGrowth": null,
        "partnerships": [
          "Moderna (CFTR mRNA therapeutic)",
          "CRISPR Therapeutics (gene-editing therapies)",
          "Entrada Therapeutics (myotonic dystrophy program)",
          "Verve Therapeutics (liver gene-editing program)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex reported strong quarterly performance with continued growth in cystic fibrosis treatments and multiple pipeline opportunities across gene therapy, pain management, and rare diseases. The company has significant cash reserves and is preparing for potential near-term product launches in sickle cell disease and beta thalassemia.",
        "keyQuotes": [
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities",
          "Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines"
        ],
        "marketData": {
          "priceOnEarningsDate": 347.8299865722656,
          "priceAfter7Days": 355.20001220703125,
          "priceChangePercent": 2.1188586146336807,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 70,
          "compositeSentimentScore": 61,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000021",
        "filingDate": "2023-08-02",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/vrtx-20230630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2493.2,
        "netIncome": 915.7,
        "operatingCashFlow": 2034.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 179.1,
        "marketShareMention": "Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 60.5,
          "Europe": 32.1,
          "Other": 7.4
        },
        "capexAmount": 101.7,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for exa-cel",
          "Moderna collaboration for VX-522 CFTR mRNA therapeutic",
          "Lonza manufacturing agreement for stem cell therapies"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q2 financial performance, with product revenues growing to $2.5 billion primarily driven by TRIKAFTA/KAFTRIO uptake. The company continues to advance a diversified pipeline across multiple therapeutic areas including cystic fibrosis, sickle cell disease, and type 1 diabetes.",
        "keyQuotes": [
          "We are evaluating our medicines in additional patient populations, including younger children",
          "We continue to advance a diversified pipeline of potentially transformative small molecule, mRNA, cell and genetic therapies",
          "Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics"
        ],
        "marketData": {
          "priceOnEarningsDate": 351.9100036621094,
          "priceAfter7Days": 338.17999267578125,
          "priceChangePercent": -3.90156882255361,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 51,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000012",
        "filingDate": "2023-05-02",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/vrtx-20230331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2374.8,
        "netIncome": 699.8,
        "operatingCashFlow": 899.9,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 236.4,
        "marketShareMention": "Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 59.1,
          "Europe": 34,
          "Other": 6.9
        },
        "capexAmount": 42.1,
        "capexGrowth": null,
        "partnerships": [
          "Moderna (CFTR mRNA therapeutic)",
          "CRISPR Therapeutics (gene-editing)",
          "Entrada Therapeutics (DM1 therapeutics)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2023 performance with $2.4B in revenues driven by TRIKAFTA/KAFTRIO uptake. The company continues to expand its pipeline across multiple disease areas including cystic fibrosis, sickle cell disease, and type 1 diabetes, while maintaining a robust financial position with $11.5B in cash and marketable securities.",
        "keyQuotes": [
          "We are evaluating our medicines in additional patient populations, including younger children",
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2025-11-26T18:10:07.688Z"
}